Iressa

Iressa: Synthetic antitumor drug from the UK

Iressa, also known by its international name Gefitinib, is a pharmaceutical drug developed and manufactured by AstraZeneca UK Ltd in the UK. It belongs to a group of synthetic anticancer drugs of different groups and is used to treat a certain type of cancer.

Iressa is presented in the form of film-coated tablets containing 250 mg of the active ingredient. The drug is used in oncology, especially to treat some forms of lung cancer, including non-small cell lung cancer that has mutations in the epidermal growth factor receptor (EGFR) gene.

Iressa's mechanism of action is to inhibit the activity of EGFR tyrosine kinase, an enzyme that plays a key role in the growth and division of cancer cells. By blocking this enzyme, Iressa helps slow tumor growth and suppress the development of cancer cells.

Iressa has been approved as a drug for the treatment of lung cancer in various countries. It is widely used in medical practice and can be prescribed by a doctor in accordance with the individual characteristics of the patient and the characteristics of his disease.

Like any medicine, Iressa may cause side effects. Some of these include rash, diarrhea, nausea, fatigue and changes in taste. It is important to discuss possible risks and side effects with your doctor before starting treatment.

Overall, Iressa represents an important advance in the treatment of lung cancers with certain genetic mutations. It allows us to provide patients with new options to combat this serious disease and increase their chances of recovery. However, the decision to use Iressa should be made by a physician based on the patient's individual characteristics and medical history.

It is important to note that this article is based on information available at the time of writing, and it is recommended that you consult current sources and consult a medical professional for more detailed information about Iressa and its use.